Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909452 · ClinicalTrials.gov registry record · Phase 1
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02909452: Completed Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, sponsored by Syndax Pharmaceuticals.
NCT02909452 is a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 30 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02909452, a Phase 1 study of Neoplasms and Carcinoma, Non-Small Cell Lung, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Entinostat
Study Locations (1)
Texas
- The START Center for Cancer Care - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2021-02-09 |
| Phase | Phase 1 |
What the finished NCT02909452 record still lists
NCT02909452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower).
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02909452 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02909452 about?
NCT02909452 is a clinical study titled "Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy
What is the current status of trial NCT02909452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-09-20. Estimated completion is 2021-02-09.
What conditions does trial NCT02909452 study?
This clinical trial studies the following conditions: Neoplasms, Carcinoma, Non-Small Cell Lung, Lung Neoplasms, Neoplasms by Histologic Type, Thoracic Neoplasms.
What interventions are being tested in trial NCT02909452?
The interventions under investigation include: Pembrolizumab (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT02909452?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02909452 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02909452's enrollment target sits among peer trials
30 134th of 158 higher than 21 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI